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ABSTRACT 
 
Niemann-Pick Type C1 (NPC1) is an autosomal neurologic pediatric orphan disease, 
with death occurring by age 20-25. It is estimated that 1 in 150,000 people in the United States 
(US) and 1 in 100,000 people in the European Union (EU) suffers from NPC1. The disease 
results from NPC1 gene mutations which cause defective protein activity, leading to harmful 
levels of cholesterol and sphingolipids in cells.  
Using data from a natural history study and a phase 1 study we investigated the efficacy 
of a potential treatment for NPC1 in patients aged 6 to 26 with multiple follow-up visits. To 
evaluate the change in severity of neurologic manifestations, we focused on nine different 
measures: dietary restrictions, diminished lip strength, diminished tongue strength, dysarthria, 
ability to consume liquids, risk of laryngeal penetration when consuming liquids or solids, ability 
to consume solids, speech difficulties, and swallowing difficulties. The primary objective of our 
analysis evaluated the efficacy of the proposed treatment in reducing the aforementioned 
symptoms of NPC1. For each symptom, a random intercept mixed-effects model was fit 
incorporating the factors of time, treatment, and their interaction as potential predictors. 
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Our strategy has certain advantages over a traditional randomized clinical trial (RCT) as it uses 
patients enrolled from an ongoing natural history study for which we already have some data on 
the progression of the disease. Furthermore, it provides a pool of patients from which to recruit 
phase 1 participants. From an analytic point of view, it provides an efficient use of the available 
data and an alternative design to an RCT that requires greater sample sizes which would be 
difficult to obtain in the setting of a rare disease. The utilization of our study design can expedite 
orphan disease research by decreasing the amount of patients necessary to reach meaningful 
conclusions from efficacy studies. For these reasons, our approach provides a practical 
alternative in evaluating efficacy of treatment in rare/orphan disease research, a very current 
public health issue. 
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1.0  INTRODUCTION 
An orphan (OD) or rare disease is generally understood to be any disease that affects a 
small proportion of a population. However, there is no universal standard for a disease to be 
recognized as a rare disease. According to the US Rare Disease Act of 2002, a rare disease is one 
that affects less than 200,000 people in the United States. In Japan, the definition of a rare 
disease is one that impacts less than 50,000 people. The European Commission on Public Health 
gives two criteria for a disease to be classified as a rare disease. The first is that the disease is 
life-threatening or chronically debilitating. The second criterion is that less than 1 in 2000 people 
suffers from it. If both of these criteria are met, then it is understood that special action is 
necessary to combat the disease.  
In fact, rare disease and orphan disease are not synonymous terms. Factors such as 
severity of disease and availability of treatment and resources help determine whether a disease 
is rare. As a result, especially after the US Orphan Drug Act was passed in 1983, rare diseases 
are commonly thought of as ODs. In fact, the Orphan Drug Act includes rare and non-rare 
diseases for which producing drugs is not expected to be profitable. 
Despite the overall low incidence of ODs, the prevalence of ODs can vary widely by 
geographic region and demographic group. Indeed, in 2011 there were about 25 million 
Americans suffering from ODs. One estimate gives the number of ODs at about 8000 and a great 
number of them are inherited genetically, affect children at very early stages in life, and have 
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grave physical effects. ODs are by definition rare and while some are relatively well-known 
(cystic fibrosis and Huntington’s disease), others have less than 100 people afflicted with that 
disease in the United States. Thus, due to the time-consuming, complicated, expensive, and 
frequently unsuccessful nature of drug development, pharmaceutical companies have little 
incentive to produce products to treat these conditions. The US Orphan Drug Act incentivized 
drug companies to produce drugs to treat orphan diseases. As a result, as of 2011, there were 
about 325 drugs on the market to treat various orphan diseases. Unfortunately, these products 
only provide treatment for about 5% of known ODs. In addition, most of these 325 drugs 
specifically treat rare cancers or metabolic diseases, resulting in a dearth of treatment options for 
diseases in other disease classes. In addition, most of these new treatment options are based on 
combating symptoms, rather than providing a cure or addressing the person’s faulty biological 
processes that are the starting point for the disease. Finally, the high cost of these products, even 
by the standards of pharmaceutical drugs, is a significant burden for patients and insurers alike. 
This is despite the efforts entailed in the Orphan Drug Act to counter those costs.  
For this research project, we studied neurologic symptoms of Niemann-Pick Type C1 
(NPC1) disease. NPC1 is an orphan disease resulting from mutations in the NPC1 gene. The 
prevalence of NPC disease is estimated to be 1 in 150,000 people in the United States (US) 
(Millat, et al., 1999) and 1 in 100,000 people in the European Union (EU) (Vanier, 2010). It is 
autosomal recessive and mostly occurs in children and teenagers, with premature death by age 
20-25.  
Niemann-Pick Type C1 (NPC1) disease is a rare, neurodegenerative, inherited, autosomal 
recessive disorder which primarily manifests in children and teenagers. Niemann-Pick Type C 
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(NPC1) is characterized by systemic disease (hepatic, splenic, pulmonary) and progressive 
neurologic manifestations including ataxia, dementia and seizures resulting in early death by the 
age of 20-25 years of age. The prevalence of NPC disease is estimated to be 1 in 150,000 people 
in the United States (US) (Millat, et al., 1999) and 1 in 100,000 people in the European Union 
(EU) (Vanier, 2010). NPC1 disease is a result of mutations in the NPC1 gene whose protein 
normally functions in neurons and other cells to transport unesterified cholesterol and 
sphingolipids from the late endosomal/lysosomal (LE/LY) compartment. To control the cellular 
concentration of cholesterol, sphingolipids and other lipids, cells have a complex trafficking 
system. Part of this system is the lipid efflux from LE/LY via the action of NPC1, at least in part. 
In patients lacking or with deficient NPC1, cholesterol, bis-(monoacylglycerol) phosphate, and 
various sphingolipids accumulate to toxic concentrations in lysosomal storage organelles. Most 
of the evidence supports that the primary storage metabolite in NPC1 disease, especially in the 
peripheral tissues, is low-density lipoprotein-derived cholesterol (Rosenbaum & Maxfield, 
2011). Cholesterol and sphingolipids are important lipids in mammalian physiology; however, in 
excessive concentrations both are toxic to cells resulting in cellular dysfunction and death. The 
neuropathological abnormalities in NPC patients that are caused by this block in cholesterol 
transport include; brain atrophy, widespread neuronal cytoplasmic vacuolization and neuronal 
loss, with the Purkinje cells being the most severely affected. 
We used data from one natural history study and one phase 1 study. The natural history 
study consisted of 78 patients with NPC disease and included assessment of disease severity, 
neuropsychiatric, ophthalmological, audiological, speech, and language pathology. Cholesterol 
metabolite measurements were taken from blood, urine, and cerebrospinal fluid (CSF). Data was 
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collected from 2006 to August 2014. Out of these 78 patients, 65 received speech evaluations 
and form the basis for the results presented here. 
We specifically examined NPC1 in natural history patients aged 6 to 26 years at entry to 
study with multiple visits and all phase 1 patients with multiple visits. In order to evaluate the 
severity of neurologic manifestations, we used nine variables: dietary restrictions, diminished lip 
strength, diminished tongue strength, dysarthria, ability to consume liquids, risk of laryngeal 
penetration when consuming liquids or solids, ability to consume solids, speech difficulties, and 
swallowing difficulties. A person with dysarthria has abnormally weak speech muscles, resulting 
in difficulty with clear articulation.  
The phase 1 study was a single center and open-label study, meaning that providers and 
patients were aware of which treatment the patient was receiving. Children with NPC1 disease 
enrolled in the study received increasingly larger doses of the treatment compound over time via 
monthly lumbar IT injections, with the goal of arresting the physical and mental deterioration 
caused by NPC1. This decline is expressed partially through various outcomes that we are 
studying: difficulty consuming solids and liquids, weakened lip and tongue muscles, dysarthria, 
risk of laryngeal penetration when ingesting liquids and solids, and speech and swallowing 
difficulties. It is also generally expressed through other avenues that we are not examining.   
There were three primary goals of the phase 1 study, the first of which was to evaluate 
the safety and tolerability of IT administration of the treatment in patients with NPC disease. The 
other primary goals were to study the study drug’s plasma pharmacokinetics after IT 
administration and use changes in plasma 24-S hydroxycholesterol level to calculate a 
biochemically active dose of the treatment. The secondary objectives were to assess the 
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employment of candidate plasma and CSF biomarkers and to carry out an exploratory appraisal 
of the utilization of clinical outcome measures in future clinical development.  
1.1 NATURAL HISTORY OF ORPHAN DISEASES 
We are interested in describing the natural history of orphan diseases. By studying the 
natural history of an orphan disease, we can glean important information regarding the timeline 
and severity of the progression of the disease. Particularly in the case of orphan diseases, being 
well-acquainted with the natural history of the disease is a valuable aid for later studies. In 
traditional medical trials involving orphan diseases, investigators usually struggle to enroll 
enough patients to have both treatment and placebo groups of sufficient size. If the natural 
progression of the disease is well-documented, then knowledge of it could potentially replace the 
traditional placebo group. Then, researchers do not need to register as many patients to have the 
same power. If the proposed drug has a large enough effect, a clinical trial with only a single 
treatment arm can be sufficient. 
Analysis of data from natural history studies can provide information for the formation of 
pertinent research hypotheses for clinical trials and outcomes to be used as endpoints. Finally, 
patients in natural history studies can be a potential source of participants for future clinical 
trials. Given the particularly acute struggles to enroll sufficient patients that orphan disease 
clinical trials face, this last point is crucial. Quick recruitment of willing patients could result in 
significant reductions in cost and time. This would give pharmaceutical companies additional 
incentive to attempt to develop treatments for orphan diseases.    
6 
The orphan disease Niemann-Pick Type C1 disease is one member of the family of 
Niemann-Pick diseases. Niemann-Pick Type C includes disorders related to certain irregularities 
in intracellular transportation of endocytosed cholesterol. Endocytosis occurs when a cell 
conveys molecules into the cell by surrounding them through the use of an energy-consuming 
process. There are two types of Niemann-Pick Type C disease: C1, which is caused by a 
mutation in the NPC1 gene and C2, which is the result of a NPC2 gene mutation. NPC1 is 
responsible for about 95% of NPC cases. In both cases, the gene mutation causes a protein to be 
unable to sufficiently remove endocytosed cholesterol from its current location, as described 
above.  
Figure 1: Study Design 
All of the phase 1 study and natural history comparison patients originated in natural 
history study. Of the 78 patients enrolled in the original natural history study, we have data for 
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65 patients in our dataset, who were then assigned to the phase 1 study or natural history 
comparison group. Patients in the phase 1 study group, akin to the treatment group in a 
randomized clinical trial (RCT), received the experimental treatment. The natural history 
comparison group patients, similar to a control group, received no treatment or placebo.  
For our analysis, we used phase 1 study patients with baseline visit information and at 
least one follow-up visit. To make the groups comparable, we selected patients aged 6-26 with 
baseline data and at least one follow-up visit for the natural history comparison group. Using this 
approach, we already have data on all of the patients. This lessoned the difficulty of finding 
sufficient numbers of treated and non-treated patients, which is especially difficult for orphan 
diseases. 
 
1.2 HYPOTHESIS OF INTEREST 
Our research project involves a potential treatment for speech and swallowing-related 
neurologic symptoms of Niemann-Pick Type C1 (NPC1) disease. The primary objective is to 
demonstrate the efficacy of the proposed treatment in reducing speech-related symptoms of 
NPC1. In order to evaluate efficacy, we will compare values of the outcome variables for the 
phase 1 and natural history patients. Our null hypothesis is that there is no significant difference 
between phase 1 and natural history patients for any of the outcome variables. Our alternative 
hypothesis is that there is a significant difference between the two groups for at least one 
outcome. 
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1.3 STATISTICAL APPROACH 
We created a generalized linear mixed model to describe the natural history of two 
different pediatric orphan diseases. Generalized linear mixed models are particularly helpful in 
situations where we have longitudinal data, but do not have fixed time points or an equal number 
of data points at each point in time. As a result of this imbalance, multivariate regression is not 
well-equipped to tackle longitudinal data. Nevertheless, for each patient, outcomes can be well-
predicted using linear regression. As a result, we can perform individual-level analysis with 
linear regression techniques and subsequently utilize multivariate regression functions to 
compare results for different patients.  
A generalized linear mixed model is derived from this combination of models. We start 
with a linear regression model with an outcome variable, Y. In that model, Y is calculated by 
adding the error and the product of the values of each predictor variable and its coefficient. We 
generally assume that the errors are independently and normally distributed with a mean of zero 
and finite variance.  
In the second step, multivariate regression is performed in order to study variability in 
patients’ regression coefficients. . The value of each dependent variable is the sum of a variable 
to measure random variability and the product of each covariate and its corresponding 
coefficient. The values of the random variability term are also assumed to be independently and 
normally distributed with a mean of zero and finite variance, similar to the error in the patient-
specific stage.  
Generally speaking, estimation of the multivariate regression parameters is the primary 
goal. The first step is to fit the linear regression model to the observed data in order to calculate 
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estimates of patient-specific regression coefficients. We then apply the multivariate regression 
function to those estimates in order to explain variability in various patients’ responses.  
There are a number of potential problems with this approach. In the first component, the 
observed data for each patient is summarized separately by an estimate, which results in lost 
information. The second occurs when we replace the outcome for the multivariate regression 
model by an estimated value for that outcome. As a result, random variability is added to the 
model. Finally, the covariance matrix of those estimates is greatly affected by the number of 
measurements for each patient and when those measurements were taken. These problems are 
addressed through the use of a general linear mixed model.  
With the general linear mixed model, we combine the linear and multivariate regression 
models into a model with three components. Indeed, “mixed” in the term “mixed models” refers 
to the mixture of fixed and random effects in the model. The first portion is the product of 
population-level variables and their regression coefficients, which comes from the multivariable 
regression model. These population-specific covariates are known as fixed effects because the 
effect on the individual’s outcome is assumed to be identical for all individuals. We will denote 
the vector containing these variables as X and the vector consisting of the corresponding 
regression coefficients as β. 
 The middle term is the product of individual-level parameters and their coefficients, 
which are the basis for the linear regression model. The patient-specific variables are known as 
random effects because their values are assumed to vary randomly from patient to patient. The 
random variability is assumed to be normally and independently distributed with a mean of zero 
and finite variance. The vector of the patient-specific covariates will be represented by Z and the 
vector of their coefficients by b.  
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The final component of our mixed model is the error term vector, ε. We assume that the 
errors are normally and independently distributed with a mean of zero and finite variance. 
Thus, for an arbitrary patient i, a linear mixed-effects model will having the following 
characteristics: 
Yi =  Xiβ + Zibi + εi 
bi is N(0, D) 
εi is N(0, ∑i) 
b1, , , bn, ε1, , , εn are independent,  
where Yi is the vector of outcome values for that patient i. We will assume that Yi and εi 
have ni components and that there are N total patients. We will further assume that β, the vector 
of fixed effects, has p elements and b, the vector of random effects, have q elements. Then, X, 
the vector of population-level covariates, is a ni x p matrix and Z, the vector of patient-level 
covariates, is a ni x q matrix. Additionally, D is a q x q matrix, where with any (i, j) element in 
D, dij = dji and ∑i is a ni x ni matrix whose parameters are not affected by the value of i and the 
latter’s only effect on ∑i is its dimension.  
Within the world of mixed models, there is the random slope model and the random 
intercept model. The random slope model is one in which we believe that variability in 
individuals’ slopes is caused by treatment differences and from variability in the patients 
themselves. If we presume that all the variability in patients’ slopes is due to differences in 
treatment of those patients, then we can omit the random slope component from the model. This 
mixed-effects model without a random slope component is known as the random intercept 
model. .          
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We treated time as a fixed effect, due to limited sample size. Our models also included 
the intercept as a random effect, as we expect some variability in their effects, even if their 
magnitudes are held constant.  
We utilized the mixed effects model to understand changes over time in the outcomes of 
interest and to understand the role of the proposed treatment in modifying the course of the 
disease. To best understand the treatment effect, we fit three mixed models for each outcome 
variable. The predictor variables for the models consisted of: time (in years) only, time and a 
treatment indicator, and both main effects and their interaction.  The results for each group of 
models are summarized in Table 2, Table A-1, and Table 3, respectively. We used a significance 
level of 0.05 for all models and treated a p-value between 0.05 and 0.20 as exhibiting a trend 
toward significance. 
We then estimated the individual slopes representing the rate of change over time using 
an estimate statement and tested for a difference in these slopes by using the significance level 
associated with the interaction term in the model. Due to the limited sample size, significance 
levels are less likely to reach a level of 0.05 or smaller, so overall trends and consistency of the 
results across endpoints are also examined. 
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2.0  RESULTS 
We utilized data for speech and swallowing-related neurological symptoms of NPC1. We 
employed scales related to dietary restriction, diminished lip strength, diminished tongue 
strength, dysarthria, liquid, risk of laryngeal penetration, solid food, speech, and swallowing. 
 
2.1 BASELINE INFORMATION 
Our first step was to obtain baseline descriptive information for these outcome variables. 
We restricted our analysis to natural history patients aged 6-26 at baseline who had multiple 
visits and all phase 1 patients with multiple visits. We calculated means and standard deviations 
for all patients, the natural history group, and the phase 1 study group for each predictor. The 
results are given in Table 1.  
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Table 1: Descriptive Information for Outcome Variables for Niemann-Pick Type C1 
Speech and Swallowing-related Neurological Symptoms and Age 
Variable All Patients 
Mean (SD) 
Natural History (N = 17) 
Mean (SD) 
Phase 1 Study (N = 11) 
Mean (SD) 
AGE (years) 15.14 (5.14) 14.35 (5.48) 16.36 (4.54) 
DIET 0.22 (0.64) 0.25 (0.77) 0.18 (0.40) 
LIP 2.30 (0.91) 2.13 (1.02) 2.55 (0.69) 
TONGUE 2.32 (0.94) 2.18 (1.07) 2.55 (0.69) 
DYSARTHRIA 2.43 (0.88) 2.35 (1.00) 2.55 (0.69) 
LIQUID 3.65 (0.68) 3.72 (0.77) 3.55 (0.52) 
PENETRATION 4.30 (1.27) 4.29 (1.45) 4.30 (0.95) 
SOLID FOOD 3.70 (0.54) 3.75 (0.58) 3.64 (0.50) 
SPEECH 1.82 (0.39) 1.76 (0.44) 1.91 (0.30) 
SWALLOWING 6.21 (1.62) 6.12 (2.00) 6.36 (0.81) 
STUDY TIME 
(years) 
1.66 (1.12) 2.19 (1.14) 0.85 (0.29) 
All of these measurements were taken at baseline, with the exception time spent enrolled 
in study. The scale to measure dietary restriction is 0-3, with a higher score indicating greater 
dietary restrictions. Specifically, it is a composite measure of the patient’s diet status with 
regards to consumption of solids and liquids. The lip and tongue weakness variables use the 
same scale, which ranges from 1-4, with larger values indicating greater levels of weakness. The 
speech and dysarthria outcomes are linked. Patients were first scored on their speech fluency. 
Those who received a grade of 1 (normal), were given a value of 1 (normal articulation) for the 
dysarthria variable. Patients with a grade of 2 for the speech variable, implying impaired speech, 
were then also given a value for the dysarthria variable, ranging from 2-4. The penetration 
variable is a measure of the risk of inhaling liquids or solids, with the risk of inhalation 
increasing as the value of the variable decreases. Swallowing was measured on a 1-7 scale, with 
higher values corresponding to greater proficiency with swallowing. Study time was defined as 
the amount of time that a patient spent in whichever study there were assigned to. Thus, even 
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though all patients began in the natural history study, for phase 1 patients, we only included their 
time spent in the phase 1 study.  
With the exception of study time, the means for each of the outcome variables and age do 
not vary significantly by patient group at baseline. The average length of time in the study was 
markedly longer for natural history patients than phase 1 study patients. In addition, the natural 
history group has larger SDs with the difference clearly non-significant in some cases, and 
possibly so in others. In the case of significant differences, that would indicate markedly greater 
variability in the scores of the natural history patients, compared to the phase 1 study patients, 
which would not necessarily entail positive or negative consequences.   
2.2 SPAGHETTI PLOTS 
As a further descriptive measure, we created spaghetti plots to visually display how each patient’s 
values change over time for each outcome of interest. For each outcome variable, we created separate 
spaghetti plots for the natural history and phase 1 studies groups. Each spaghetti plot incorporated a 
separate line for each patient. We used years enrolled in the study as the x-axis variable. The spaghetti plots 
for level of dietary restrictions over time for phase 1 and natural history follow. 
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Figure 2.  Restrictions on Solid and Liquid Consumption 
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Figure 3: Restrictions on Solid and Liquid Consumption 
There are some noticeable differences between the two groups, starting with the 
difference in time spent in the study.  The average amount of time spent in the study for the 
phase 1 patients was 0.85 years, with a maximum of about 1.36 years. The natural history group 
mean was 2.19 years, with a maximum of about 4.44.   
The dietary restriction variable is a composite measure of the patient’s restrictions on 
consumptions of solids and liquids with a higher score indicating greater dietary restrictions. In 
the phase 1 group, two patients’ scores increased from zero (no dietary restrictions) to one (diet 
is one level below regular diet status in solid or liquid consistency). These levels are the various 
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values for the solid food and liquid variables, which are shown in Figure A-1 in the appendix. 
Another patient’s score increased from zero to two (two levels below regular diet status with 
liquids and solids combined or in either). All of the other phase 1 patients remained constant 
with a value of zero or one for the duration of their time in the study.  
In the natural history group, two patients maintained a score of three (diet is at least two 
levels below regular diet status with both liquids and solids) for the entirety of their participation 
in the study. Also unlike the phase 1 study group where there were no improvements, one patient 
was able to downgrade their evaluation from one to zero. The rest of the natural history group 
was similar to the phase 1 study group, with two patients worsening from zero to one, one patient 
deteriorating from zero to two, and the rest remaining constant. Thus, from this descriptive work, 
it appears that the treatment does not significantly affect the neurological symptoms of Niemann-
Pick Type C1 disease. In other words, the natural history and phase 1 patients are experiencing 
similar severity for the NPC1 neurologic symptoms of interest. 
 
2.3 MIXED MODELS 
In order to formally test the significance of treatment and time, for each outcome 
variable, we created three mixed models: time as the only predictor, time and an indicator for 
involvement in the phase 1 study, and both main effects and their interaction. The results are 
summarized in Tables 2, A-1, and 3, respectively.  
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With regards to the time-only models, diminished tongue strength (p = 0.033), solid food 
(p = 0.011), and swallowing (p = 0.018) were significant. The coefficients for those three models 
were 0.080, -0.156, -0.163, respectively, demonstrating changes over time in the full population.  
With the solid food scale, a lower score indicates a decreased ability to consume solid 
foods. Thus, the negative coefficient for the solid food variable points to further restrictions in 
solid ingestion over time. On the swallowing scale, a lower value also corresponds to decreased 
physical ability. As a result, the negative coefficient for the swallowing outcome variable 
similarly implies a decreased capability to swallow. By contrast, with the diminished tongue 
strength scale, a higher score refers to a worse physical state. Thus, the positive coefficient 
indicates greater weakness of the tongue muscles over time. Hence, all three variables 
demonstrate that NPC patients decrease in physical ability as time goes on. 
In addition, diminished lip strength and liquid showed a trend toward significance, with 
p-values of 0.127 and 0.119 and coefficients of 0.047 and -0.090, respectively. Akin to the 
diminished tongue strength scale, a higher value for the diminished lip strength variable indicates 
increased muscle weakness. Therefore, the positive coefficient for this variable demonstrates 
further decrease in physical ability over time. The liquid variable scale, similar to the solid food 
scale, assigns lower values to patients with greater physical impairment. As a result, the liquid 
variable’s negative coefficient also implies reduced physical abilities. Thus, all five of the 
significant time-only models point to reduced physical and mental capabilities for NPC1 patients 
over time. As a result, time appears to have a significant role to play in the severity of NPC1 
symptoms when not considering other factors. 
Time was a significant predictor of diminished tongue strength, solid food restrictions, 
and swallowing difficulty in the models with both main effects, with coefficients of 0.082, -
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0.162, and -0.163 and p-values equal to 0.028, 0.009, and 0.019, respectively. As addressed in 
the previous paragraph, the signs of all three coefficients indicate a worsening in physical 
capability over time. Time exhibited a trend toward significance in the diminished lip strength (p 
= 0.109) and liquid restrictions (p = 0.084) models, with corresponding coefficients of 0.050 and 
-0.101. Once again, all of the models in which time is a significant or close to significant factor 
paint a picture of decreased physical ability over time.  
The indicator for involvement in the phase 1 study was not a significant factor for any of 
the outcome variables in this group of models, although there was a trend toward significance in 
the diminished lip strength (p = 0.172), liquid restrictions (p = 0.143), and speech (p = 0.099) 
models. Those three models’ coefficients were 0.479, -0.409, and 0.209. With the diminished lip 
strength and speech scales, larger values indicate increased weakness and difficulty, respectively. 
The liquid restrictions scale works in the opposite direction, with smaller values corresponding to 
more restrictions on consumption of liquids. The indicator for phase 1 study involvement equals 
one for a phase 1 patient and zero for a natural history patient. Therefore, the signs of these 
coefficients point to lower physical abilities for these three outcomes in the phase 1 study group, 
relative to the natural history group.  
In the full models, time was a significant predictor of diminished tongue strength (p = 
0.033) and solid food restrictions (p = 0.023) and coefficients equal to 0.083 and -0.147, 
correspondingly. Again, these results imply increased physical disability as time goes on. Time 
was also a borderline significant predictor of swallowing difficulties (p = 0.057) and had a trend 
toward significance in the diminished lip strength model, with a p-value of 0.136. The 
corresponding coefficients of -0.134 and 0.049 reinforce the notion of physical deterioration as 
time goes on.  
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The indicator component was not significant for any of the models, although it trended 
toward significance in the diminished lip strength (p = 0.184) and speech difficulties (p = 0.179) 
models. In those two models, the coefficients for the indicators were 0.472 and 0.179, 
respectively. Similar to the main effects-only models, this would point to lower physical abilities 
in the phase 1 patients compared to the natural history patients.  
The interaction between time and the treatment indicator was not statistically significant 
in any of these models, although there was a trend toward significance in the dietary restrictions, 
liquid restrictions, and swallowing difficulties models, with coefficients of 0.334, -0.324, and -
0.373 and p-values of 0.094, 0.134, and 0.138, respectively. The signs of the coefficients all 
imply that phase 1 patients worsen more quickly over time than natural history patients.  
Time was a significant predictor of diminished tongue strength and solid food in all three 
groups of models. In addition, it was a statistically significant covariate for swallowing in the 
time-only and both main effects models and borderline statistically significant in the full model. 
Time also displayed a trend toward significance for diminished lip strength in all three groups of 
models. In all cases, the signs of the coefficients indicated that physical outcomes worsen as time 
goes on. 
The indicator was never a statistically significant factor, although it exhibited a trend 
toward significance for diminished lip strength and speech difficulties in both sets of models. 
The coefficients for the indicator in those cases indicated a worse prognosis for phase 1 patients, 
compared to natural history patients. The lack of statistical significance, with only a trend toward 
significance present, makes that conclusion tenuous. Similarly, the interaction displays a trend 
toward significance for the dietary restrictions, liquid restrictions, and swallowing difficulties 
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variables, but no statistical significance. As a result, the conclusion that phase 1 patients 
physically deteriorated over time faster than natural history patients is similarly tenuous. 
Table 2: Time-only Mixed Models Results for Outcome Variables for Niemann-Pick Type 
C1 Speech and Swallowing-related Neurological Symptoms  
Outcome Time p-value 
Diet 0.066 0.221 
Lip 0.047 0.127 
Tongue 0.080 0.033* 
Dysarthria 0.043 0.276 
Liquid -0.090 0.119 
Penetration -0.085 0.356 
Solid food -0.156 0.011* 
Speech 0.002 0.935 
Swallowing -0.163 0.018* 
*: p-value < .05 
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Table 3: Full Mixed Models Results for Outcome Variables for Niemann-Pick Type C1 
Speech and Swallowing-related Neurological Symptoms 
Outcome Time p-value Treatment group p-value Interaction p-value 
Diet 0.039 0.481 -0.257 0.429 0.334 0.094 
Lip 0.049 0.136 0.472 0.184 0.014 0.904 
Tongue 0.083 0.033* 0.423 0.261 -0.018 0.896 
Dysarthria 0.043 0.301 0.241 0.474 0.030 0.841 
Liquid -0.077 0.201 -0.245 0.408 -0.324 0.134 
Penetration -0.064 0.507 -0.038 0.941 -0.387 0.283 
Solid food -0.147 0.023 -0.107 0.730 -0.201 0.376 
Speech 0.005 0.873 0.179 0.191 0.059 0.589 
Swallowing -0.134 0.057 0.253 0.709 -0.373 0.138 
*: p-value < .05 
2.4 DIFFERENCE IN SLOPES 
In order to test the significance of the interaction between time and the indicator for 
involvement in the phase 1 study, we used estimate statements to calculate the slopes for each 
study group in the full group and determined the probability of a statistically significant 
difference between the slopes. The results are show in Table 4.  There is a trend toward 
significance in the dietary restrictions (p = 0.094), liquid restrictions (p = 0.134), and swallowing 
difficulties (p = 0.138). In all three cases, the magnitude of the slope for the phase 1 group is 
greater than for the natural history group. In the case of the dietary restriction outcome, both 
slopes are positive, whereas for the liquid and swallowing variables, both coefficients are 
negative. With the dietary restriction variable, larger values indicate greater restrictions on diet. 
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By contrast, the liquid and swallowing scales work in the opposite manner, with smaller values 
corresponding to increased limitations. Therefore, these results, however tenuous significance-
wise, would seem to imply greater severity of symptoms among phase 1 patients than natural 
history patients, calling into question the efficacy of the experimental treatment. 
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Table 4: Differences in Niemann-Pick C1 Disease Swallowing and Speech-related 
Neurologic Symptom Outcomes by Study Group     
Outcome Phase 1 
(SE) 
Natural 
History 
Slope 
(SE) 
p-value for 
difference 
Diet 0.372 
(0.187) 
0.039 
(0.054) 
0.094 
Lip 0.063 
(0.109) 
0.049 
(0.032) 
0.904 
Tongue 0.065 
(0.132) 
0.083 
(0.038) 
0.896 
Dysarthria 0.073 
(0.143) 
0.043 
(0.041) 
0.841 
Liquid -0.401 
(0.204) 
-0.077 
(0.059) 
0.134 
Penetration -0.451 
(0.343) 
-0.064 
(0.095) 
0.283 
Solid food -0.347 
(0.216) 
-0.147 
(0.062) 
0.376 
Speech 0.064 
(0.105) 
0.005 
(0.030) 
0.589 
Swallowing -0.507 
(0.237) 
-0.134 
(0.069) 
0.138 
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2.5 DIAGNOSTICS 
To determine the best model for each outcome variable, we compared the AIC and BIC 
among each variable’s three models. The results are summarized in Table 5.  
Table 5: AIC and BIC Values for Mixed Models for Outcome Variables for 
Niemann-Pick Type C1 Speech and Swallowing-related Neurological Symptoms 
AIC BIC 
Variable Time 
only 
Both 
main 
effects 
Full 
model 
Time 
only 
Both 
main 
effects 
Full 
model 
Diet 148.9 149.4 147.9 151.6 152.0 150.6 
Lip 103.8 102.2 104.7 106.5 104.8 107.3 
Tongue 124.2 123.1 125.2 126.8 125.7 127.8 
Dysarthria 124.5 124.3 126.3 127.2 127.0 128.9 
Liquid 149.5 148.0 147.0 152.1 150.7 149.6 
Penetration 220.8 220.2 219.3 223.5 222.9 221.9 
Solid food 154.0 154.2 154.5 156.7 156.8 157.2 
Speech 46.7 46.3 48.6 49.4 48.9 51.2 
Swallowing 211.0 210.0 208.7 213.7 212.7 211.4 
AIC and BIC are measures of the quality of the model and can be used to compare the 
relative validity of nested models. Using these criteria, the full model was the best choice for the 
dietary restriction, liquid restrictions, risk of laryngeal penetration, and swallowing difficulties 
variables.  The model with just the main effects was the best choice of the three for the 
diminished lip strength, diminished tongue strength, dysarthria, and speech difficulties models. 
The solid food outcome variable was the only dependent variable for which the time-only model 
had the lowest AIC and BIC values. Thus, it would seem that the model with both main effects 
might be the best choice because it is simpler than the full model.  
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We performed diagnostics on the mixed models to assess the assumptions.  Due to the 
presence of a random intercept in our mixed models, we utilized the conditional residuals. We  
used categorical outcomes, so patterns in the residuals do not indicate a defect in our model. We 
examined histograms of the conditional residuals and quantile-residual plots in order to 
determine if the residuals were normally distributed. Most of the residuals did not appear to be 
clearly non-normally distributed. Some of the residuals did seem to be non-normally distributed, 
which is probably in part due to our small sample size, a common problem in orphan disease 
studies. 
 
We used Cook’s distance to determine if there were any overly influential points.  Using 
a value of one as a threshold value for influence, we did not encounter any unduly influential 
points.    
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3.0  CONCLUSION 
We wanted to evaluate the efficacy of a treatment for Niemann-Pick Type C1 disease. 
We used nine outcome variables to test for a difference: dietary restriction, diminished lip 
strength, diminished tongue strength, dysarthria, liquid restrictions, risk of laryngeal penetration, 
solid food restrictions, speech difficulties, and swallowing difficulties. As an exploratory step, 
we used proc means in SAS and patient-level spaghetti plots to look for differences by treatment 
group. These descriptive steps did not indicate a significant difference in severity of neurological 
symptoms of NPC 1 between phase 1 study patients and natural history study patients.  
We utilized mixed-effects models to determine which predictor variables significantly 
affected or had a trend toward significantly affecting each outcome variable. Time is likely a 
significant factor in tongue strength and difficulty with solid food, due to its statistical 
significance in all three groups of models for those two variables. Additionally, it appears to also 
play a significant role in swallowing difficulties, because it was a statistically significant 
covariate for swallowing in the time-only and both main effects models and borderline 
statistically significant in the full model. Time is also possibly a factor to consider in lip strength, 
due to the exhibition of a trend toward significance in all three sets of models. 
The indicator was never a statistically significant factor, although it exhibited a trend 
toward significance for diminished lip strength and speech difficulties in both sets of models that 
it was involved in, indicating the possibility of a relationship.  
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The interaction between time and the treatment indicator was not statistically significant 
in any of these models, although there was a trend toward significance in the dietary restrictions, 
liquid restrictions, and swallowing difficulties models, so it may be a factor to consider for those 
symptoms.   
For each outcome variable, we compared the AIC and BIC values among the three 
groups of models. The full model and model with only the main effects were the best choice for 
four outcome variables each, indicating that each of them is a superior choice to the time-only, 
but not clarifying the supremacy of either model.  
We employed histograms of the conditional residuals and quantile-residual plots to test 
the assumption of normality of residuals. The conditional residuals for most of the models did 
not appear to be significantly non-normally distributed. Some plots did show some non-normal 
behavior, in all likelihood partially due to our small sample size, which is a weak point of our 
study. Small sample sizes are a common problem in orphan disease studies, and hopefully a 
future study could be conducted with a larger sample size. 
 We studied the efficacy of a potential treatment for Niemann-Pick Type C1 disease, 
which has a lengthy period of decreasing physical ability associated with neurological 
symptoms, before culminating in early death. Due to the severe toll of the disease on the patient 
and all people involved in the patient’s care, efforts to minimize the burden of NPC1 are 
certainly relevant to public health.  
The limited sample sizes, due to the rarity of NPC1, are a hindrance in evaluating 
treatment efficacy. Our study design can partially mitigate some of the problems associated with 
the small sample sizes. From an existing natural history study, we created phase 1 study and 
natural history groups, similar to the treatment and placebo groups in a more traditional parallel 
 29 
group randomized clinical trial (RCT). This strategy has certain advantages over a traditional 
RCT. It uses patients enrolled in an ongoing natural history study for which we already have 
some data on progression of the disease. Furthermore, it provides a pool of patients from which 
to recruit phase 1 participants. Additionally, from an analytic point of view, it provides an 
efficient use of the available data and an alternative design to an RCT that requires greater 
sample sizes which would be difficult to obtain in our setting of a rare disease. The utilization of 
our study design can expedite orphan disease research by decreasing the amount of patients 
necessary to reach meaningful conclusions from efficacy studies. For these reasons, our approach 
provides a practical alternative in evaluating efficacy of treatment in rare/orphan disease 
research, a very current public health issue. 
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APPENDIX A: Main effects-only mixed model results 
Table 6: Both Main Effects Mixed Models Results for Outcome Variables for Niemann-
Pick Type C1 Speech and Swallowing-related Neurological Symptoms 
Outcome Time p-value Indicator p-value 
Diet 0.065 0.235 -0.089 0.773 
Lip 0.050 0.109 0.479 0.172 
Tongue 0.082 0.028 0.414 0.262 
Dysarthria 0.045 0.252 0.256 0.437 
Liquid -0.101 0.084 -0.409 0.143 
Penetration -0.091 0.326 -0.239 0.617 
Solid food -0.162 0.009 -0.209 0.473 
Speech 0.009 0.748 0.209 0.099 
Swallowing -0.163 0.019 0.068 0.919 
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APPENDIX B: Outcome scales 
Table 7: Scale for Swallowing Difficulties among Niemann-Pick Type C1 Patients 
Leve1 Description 
1 Individual is not able to swallow anything by mouth. All nutrition and hydration are 
received through non-oral means. 
2 Individual is not able to swallow safely by mouth for nutrition and hydration, but may 
take some consistency with consistent maximal cues in therapy only. Alternative 
method of feeding is required. 
3 Alternative method of feeding is required as individual takes less than 50% of nutrition 
and hydration by mouth and/or swallowing is safe with consistent use of moderate cues 
to use compensatory strategies and/or maximal diet restriction. 
4 Swallowing is safe, but usually requires moderate cues to use compensatory strategies 
and/or the individual has moderate diet restrictions and/or still requires tube feeding 
and/or oral supplements. 
5 Swallowing is with minimal diet restriction and/or occasionally requires minimal cueing 
to use compensatory strategies. The individual may occasionally self-cue. All nutrition 
and hydration needs are met by mouth at mealtime.  
6 Swallowing is safe and the individual eats and drinks independently and may rarely 
require minimal cueing. The individual usually self-cues when difficulty occurs. May 
need to avoid specific food items (e.g. popcorn, nuts) or require additional time (due to 
dysphagia).  
7 The individual’s ability to eat independently is not limited by swallow functions. 
Swallowing would be safe and efficient for all consistencies. Compensatory strategies 
are effectively used when needed. 
32 
Table 8: Scale for Scale for Solid Food Restrictions among Niemann-Pick Type C1 Patients 
Solid Food Restrictions Description Code 
Regular No restrictions 4 
Reduced one level (soft) Meats are cooked until soft with no tough 
or stringy foods. Might include meats like 
meat loaf, baked fish, and soft chicken. 
Vegetables are cooked soft. 
3 
Reduced two levels (mechanical soft) Meats are chopped or ground. Vegetables 
are of one consistency  
2 
Reduced three levels (puree) Meats and vegetables are pureed 1 
Table 9: Scale for Liquid Restrictions among Niemann-Pick Type C1 Patients 
Liquid Restrictions Description Code 
Regular Thin liquids, no restrictions 4 
Reduced one level (soft) Mildly thick liquids (e.g. nectar syrup) 3 
Reduced two levels (mechanical soft) Moderately thick liquids (e.g. honey) 2 
Reduced three levels (puree) Extra thick liquids (e.g. pudding) 1 
Table 10: Scale for Dietary Restrictions among Niemann-Pick Type C1 Patients 
Level of Restriction Description Code 
Maximum Diet is two or more levels below a regular 
diet status in both solid and liquid 
consistency 
3 
Moderate Diet is two or more levels below a regular 
diet status in solid or liquid consistency 
(but not both) or diet is one level below in 
both solid and liquid consistency 
2 
Minimum Diet is one levels below a regular diet 
status in both solid and liquid consistency 
1 
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Table 11: Scale for Lip/Tongue Weakness among Niemann-Pick Type C1 Patients 
Description Code 
Normal (no weakness) 1 
Mild 2 
Moderate 3 
Severe 4 
Table 12: Scale for Speech Fluency among Niemann-Pick Type C1 Patients 
Description Code 
Normal 1 
Impaired 2 
Table 13: Scale for Risk of Laryngeal Penetration among Niemann-Pick Type C1 Patients 
Description Code 
aspiration 50-90% 1 
aspiration 10-50% 2 
Contrast enters the airway consistently on one or more textures 3 
Risk minimal: intermittent laryngeal penetration with 
retrograde excursion on one or more textures 
4 
No obvious risk: contrast does not enter the airway 5 
Table 14: Scale for Dysarthria among Niemann-Pick Type C1 Patients 
Description Code 
Normal (no dysarthria) 1 
Mild 2 
Moderate 3 
Severe 4 
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APPENDIX C: SAS Code 
I. Baseline.sas 
proc format; 
  value F_PH1F 
  0 = "NATURAL HISTORY PATIENT" 
  1 = "PHASE 1 PATIENT"; 
  value F_RIGHT_AGEF 
  0 = "NOT BETWEEN 6 AND 26 YEARS OLD" 
  1 = "BETWEEN 6 AND 26 YEARS OLD"; 
  value F_PH1_VISITF 
  0 = "NATURAL HISTORY VISIT" 
  1 = "PHASE 1 VISIT"; 
  value F_1ST_PH1_VISITF 
  0 = "NOT 1ST PHASE 1 VISIT" 
  1 = "1ST PHASE 1 VISIT"; 
run; 
* Definition of program-specific macros;
*create macro to do descriptive analysis for each outcome variable;
%macro DESCRIPTIVE_SPEECH (DATA = , BYVAR = ); 
proc sort data = &DATA; 
   by &BYVAR; 
run; 
ods rtf file = "E:\Proj\Cydan\Programs\MB 
Programs\Out\BASELINE_DESCRIPTIVE\&DATA._BY_STUDY.rtf"; 
title "&DATA. OUTCOME VARIABLE BASELINE INFORMATION by &BYVAR."; 
proc means data = &DATA mean std maxdec = 2; 
  class &BYVAR; 
   var AGE_NEW DIETARY_RESTRICTION DIMINISHED_LIP_STRENGTH 
DIMINISHED_TONGUE_STRENGTH DYSARTHRIA LIQUID PENETRATION_ASP_CORRECTED 
SOLID_FOOD SPEECH SWALLOWING_OUTCOME; 
run; 
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proc freq data = &DATA; 
   by &BYVAR; 
   table DIETARY_RESTRICTION DIMINISHED_LIP_STRENGTH 
DIMINISHED_TONGUE_STRENGTH DYSARTHRIA LIQUID PENETRATION_ASP_CORRECTED 
SOLID_FOOD SPEECH SWALLOWING_OUTCOME / missing; 
run; 
 
proc gchart data = &DATA; 
   by &BYVAR; 
   vbar DIETARY_RESTRICTION DIMINISHED_LIP_STRENGTH 
DIMINISHED_TONGUE_STRENGTH DYSARTHRIA LIQUID PENETRATION_ASP_CORRECTED 
SOLID_FOOD SPEECH SWALLOWING_OUTCOME / discrete; 
run; quit;  
 
proc univariate data = &DATA; 
   by &BYVAR; 
   var DIETARY_RESTRICTION DIMINISHED_LIP_STRENGTH DIMINISHED_TONGUE_STRENGTH 
DYSARTHRIA LIQUID PENETRATION_ASP_CORRECTED SOLID_FOOD SPEECH 
SWALLOWING_OUTCOME; 
   histogram DIETARY_RESTRICTION DIMINISHED_LIP_STRENGTH 
DIMINISHED_TONGUE_STRENGTH DYSARTHRIA LIQUID PENETRATION_ASP_CORRECTED 
SOLID_FOOD SPEECH SWALLOWING_OUTCOME / normal; 
run; 
ods rtf close; 
 
ods rtf file = "E:\Proj\Cydan\Programs\MB 
Programs\Out\BASELINE_DESCRIPTIVE\&DATA._ALL_PATIENTS.rtf"; 
title "&DATA. OUTCOME VARIABLE BASELINE INFORMATION"; 
proc means data = &DATA mean std maxdec = 2; 
   var AGE_NEW DIETARY_RESTRICTION DIMINISHED_LIP_STRENGTH 
DIMINISHED_TONGUE_STRENGTH DYSARTHRIA LIQUID PENETRATION_ASP_CORRECTED 
SOLID_FOOD SPEECH SWALLOWING_OUTCOME; 
run; 
 
proc freq data = &DATA; 
   table DIETARY_RESTRICTION DIMINISHED_LIP_STRENGTH 
DIMINISHED_TONGUE_STRENGTH DYSARTHRIA LIQUID PENETRATION_ASP_CORRECTED 
SOLID_FOOD SPEECH SWALLOWING_OUTCOME / missing; 
run; 
 
proc gchart data = &DATA; 
   vbar DIETARY_RESTRICTION DIMINISHED_LIP_STRENGTH 
DIMINISHED_TONGUE_STRENGTH DYSARTHRIA LIQUID PENETRATION_ASP_CORRECTED 
SOLID_FOOD SPEECH SWALLOWING_OUTCOME / discrete; 
run; quit;  
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proc univariate data = &DATA; 
   var DIETARY_RESTRICTION DIMINISHED_LIP_STRENGTH DIMINISHED_TONGUE_STRENGTH 
DYSARTHRIA LIQUID PENETRATION_ASP_CORRECTED SOLID_FOOD SPEECH 
SWALLOWING_OUTCOME; 
   histogram DIETARY_RESTRICTION DIMINISHED_LIP_STRENGTH 
DIMINISHED_TONGUE_STRENGTH DYSARTHRIA LIQUID PENETRATION_ASP_CORRECTED 
SOLID_FOOD SPEECH SWALLOWING_OUTCOME / normal; 
run; 
ods rtf close; 
%mend DESCRIPTIVE_SPEECH; 
 
 
 
 
*======================================= MAIN PROGRAM 
=========================================>; 
 
 
 
*****************************************************************************
*******SPEECH_FINAL 
CODE*************************************************************************
**********; 
data SPEECH_FINAL; 
   set ANALYSIS.SPEECH_FINAL (rename = (DIMINISHED_TONGUE_STENGTH = 
DIMINISHED_TONGUE_STRENGTH)); 
   by SUBJID_NPC; 
   if(first.SUBJID_NPC and ASTDY = 0) then ASTDY_YRS = 0; 
   if (first.SUBJID_NPC and last.SUBJID_NPC) then delete; *only interested in 
patients with at least one follow-up visit; 
   if (COHORT ge 1 and COHORT le 4) then F_PH1 = 1; 
   else F_PH1=0; 
   format F_PH1 F_PH1F.; 
   if F_PH1 = 0 then  
      if (first.SUBJID_NPC and AGE_NEW ge 6 and AGE_NEW le 26) then /*if NH 
patient is in desired age range at baseline*/ 
      do; 
         F_RIGHT_AGE = 1; 
         retain F_RIGHT_AGE; 
      end; 
    else if (first.SUBJID_NPC and (AGE_NEW lt 6 or AGE_NEW gt 26)) then  
      do; 
         F_RIGHT_AGE = 0; 
         retain F_RIGHT_AGE; 
      end; 
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   if (F_PH1 = 0 and F_RIGHT_AGE = 0) then delete; *get rid of NH patients 
that aren't between 6 and 26 years old at baseline; 
   label F_RIGHT_AGE  = "flag for being between 6 and 26 years old"; 
   format F_RIGHT_AGE F_RIGHT_AGEF.; 
run; 
 
*need to get rid of time spent on natural history study for phase 1 patients; 
data SPEECH_NH_PH1_POST2013; *doesn't include natural history records for 
phase 1 patients; 
  set SPEECH_FINAL; 
  by SUBJID_NPC; 
  informat DOE mmddyy10.; *get SAS date value for visit dates; 
  BASE_SAS_DATE_VALUE = mdy(1,1,2013); *get SAS date value for Jan 1, 2013; 
 
  *create indicator for phase 1 visit; 
   if(F_PH1 = 1 and yrdif(BASE_SAS_DATE_VALUE, DOE, 'ACT/ACT') > 0) then 
F_PH1_VISIT = 1; 
   else F_PH1_VISIT = 0; 
   label F_PH1_VISIT = "PHASE 1 VISIT INDICATOR"; 
   format F_PH1_VISIT F_PH1_VISITF.; 
 
   *determine first phase 1 visit; 
   if F_PH1_VISIT = 0 then NUM_PH1_VISITS = 0; 
   else NUM_PH1_VISITS = NUM_PH1_VISITS + 1; 
   retain NUM_PH1_VISITS; 
   label NUM_PH1_VISITS = "NUMBER OF PHASE 1 VISITS"; 
 
   if NUM_PH1_VISITS = 1 then F_1ST_PH1_VISIT = 1; 
   else F_1ST_PH1_VISIT = 0; 
   label F_1ST_PH1_VISIT = "1st PHASE 1 VISIT INDICATOR"; 
   format F_1ST_PH1_VISIT F_1ST_PH1_VISITF.; 
 
   *calculate time on phase 1 study; 
   if F_1ST_PH1_VISIT = 1 then  
      do; 
         DOE_1ST_PH1_VISIT = DOE; 
         retain DOE_1ST_PH1_VISIT; 
      end; 
   if F_PH1_VISIT = 0 then DOE_1ST_PH1_VISIT = .; *make missing for all non-
phase 1 visits; 
   if (F_PH1 = 1 and F_PH1_VISIT = 0) then PH1_YRS = 0; 
   else if F_PH1 = 1 then PH1_YRS = yrdif(DOE_1ST_PH1_VISIT, DOE, 'ACT/ACT'); 
   else PH1_YRS = 0; 
   label DOE_1ST_PH1_VISIT = "SAS DATE VALUE FOR 1ST PH1 VISIT"; 
   label PH1_YRS = "NUMBER OF YEARS ON PHASE 1 STUDY"; 
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   format PH1_YRS 5.2; *5 spaces for number in all: 2 decimal places, 1 for 
decimal, which leaves 2 places left of decimal; 
 
  *calculate time that phase 1 patients spent on natural history study; 
   if F_PH1 = 1  then NH_YRS = ASTDY_YRS - PH1_YRS; 
   else NH_YRS = ASTDY_YRS; 
   label NH_YRS = "NUMBER OF YEARS IN NH STUDY"; 
   format NH_YRS 5.2; *5 spaces for number in all: 2 decimal places, 1 for 
decimal, which leaves 2 places left of decimal; 
   
 
  if (F_PH1 = 1 and F_PH1_VISIT = 1) then ASTDY_YRS = PH1_YRS; 
  else if (F_PH1 = 1 and F_PH1_VISIT = 0) then ASTDY_YRS = 0; 
  else if F_PH1 = 0 then ASTDY_YRS = NH_YRS; 
  *drop PH1_YRS NH_YRS; 
 
   if (F_PH1_VISIT = 0 and F_PH1 = 1) then delete; *delete non-phase 1 
records for phase 1 patients;   
run; 
 
data TEST; 
   set SPEECH_NH_PH1_POST2013; 
   keep SUBJID_NPC F_PH1 ASTDY_YRS F_PH1_VISIT PH1_YRS NH_YRS; 
run; 
 
data SPEECH_FINAL_BL; 
   set SPEECH_NH_PH1_POST2013; 
   by SUBJID_NPC; 
   if first.SUBJID_NPC; 
run; 
 
*get mean and SDs for time on study by study and overall; 
data SPEECH_FINAL_FINAL; 
   set SPEECH_NH_PH1_POST2013; 
   by SUBJID_NPC; 
   if last.SUBJID_NPC; 
run; 
 
proc sort data = SPEECH_FINAL_FINAL; 
   by F_PH1; 
run; 
 
ods rtf file = "E:\Proj\Cydan\Programs\MB 
Programs\Out\DESCRIPTIVE\YEARS.rtf"; 
title "TIME ON STUDY by F_PH1"; 
proc means data = SPEECH_NH_PH1_POST2013 mean max std maxdec = 2; 
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   class F_PH1; 
   var ASTDY_YRS; 
run; 
 
title "TIME ON STUDY"; 
proc means data = SPEECH_FINAL_FINAL mean std maxdec = 2; 
   var ASTDY_YRS; 
run; 
ods rtf close; 
 
%DESCRIPTIVE_SPEECH (DATA = SPEECH_FINAL_BL, BYVAR = F_PH1); 
 
 
 
 
 
/*proc contents data = SPEECH_FINAL; 
run;*/ 
 
 
 
 
proc means data = SPEECH_FINAL_PH1; 
   var ASTDY_YRS; 
run; 
 
 
proc means data = SPEECH_FINAL_NH; 
   var ASTDY_YRS; 
run; 
 
 
/*proc freq data = ANALYSIS.SPEECH_FINAL; 
   table SWALLOWING_OUTCOME; 
run;*/ 
 
data NH_PATIENTS; 
   set ANALYSIS.SPEECH_FINAL; 
   by SUBJID_NPC; 
   if (COHORT ge 1 and COHORT le 4) then delete; 
   if last.SUBJID_NPC; 
run; 
 
proc means data = NH_PATIENTS; 
   var ASTDY_YRS; 
run; 
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II. F_spaghetti_MB.sas 
proc format; 
   value F_PH1F  
      0 = "NATURAL HISTORY PATIENT" 
      1 = "PHASE 1 PATIENT"; 
   value F_RIGHT_AGEF 
      0 = "NOT BETWEEN 6 AND 26 YEARS OLD" 
      1 = "BETWEEN 6 AND 26 YEARS OLD"; 
   value F_PH1_VISITF 
      0 = "NATURAL HISTORY VISIT" 
      1 = "PHASE 1 VISIT"; 
   value F_1ST_PH1_VISITF 
      0 = "NOT 1ST PHASE 1 VISIT" 
      1 = "1ST PHASE 1 VISIT"; 
run; 
 
data SPEECH_FINAL; 
   set ANALYSIS.SPEECH_FINAL; 
   by SUBJID_NPC; 
   DIMINISHED_TONGUE_STRENGTH = DIMINISHED_TONGUE_STENGTH; 
   drop DIMINISHED_TONGUE_STENGTH; 
   label DIMINISHED_TONGUE_STRENGTH = "DIMINISHED TONGUE STRENGTH"; 
   if (first.SUBJID_NPC and last.SUBJID_NPC) then delete; 
   if (ASTDY_YRS = . and first.SUBJID_NPC and ASTDY = 0) then ASTDY_YRS = 0; 
   if (COHORT ge 1 and COHORT le 4) then F_PH1 = 1; 
   else F_PH1 = 0; 
   label F_PH1 = "INDICATOR FOR PHASE 1 STUDY"; 
   format F_PH1 F_PH1F.; 
 
   label F_RIGHT_AGE  = "flag for being between 6 and 26 years old"; 
   format F_RIGHT_AGE F_RIGHT_AGEF.; 
   if (first.SUBJID_NPC and AGE_NEW ge 6 and AGE_NEW le 26) then  
      do; 
         F_RIGHT_AGE = 1; 
         retain F_RIGHT_AGE; 
      end; 
    else if (first.SUBJID_NPC and (AGE_NEW lt 6 or AGE_NEW gt 26)) then  
      do; 
         F_RIGHT_AGE = 0; 
         retain F_RIGHT_AGE; 
      end; 
run; 
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data SPEECH_NH_PH1_POST2013; *doesn't include natural history records for 
phase 1 patients; 
  set SPEECH_FINAL; 
  by SUBJID_NPC; 
  informat DOE mmddyy10.; *get SAS date value for visit dates; 
  BASE_SAS_DATE_VALUE = mdy(1,1,2013); *get SAS date value for Jan 1, 2013; 
 
  *create indicator for phase 1 visit; 
   if(F_PH1 = 1 and yrdif(BASE_SAS_DATE_VALUE, DOE, 'ACT/ACT') > 0) then 
F_PH1_VISIT = 1; 
   else F_PH1_VISIT = 0; 
   label F_PH1_VISIT = "PHASE 1 VISIT INDICATOR"; 
   format F_PH1_VISIT F_PH1_VISITF.; 
 
   *determine first phase 1 visit; 
   if F_PH1_VISIT = 0 then NUM_PH1_VISITS = 0; 
   else NUM_PH1_VISITS = NUM_PH1_VISITS + 1; 
   retain NUM_PH1_VISITS; 
   label NUM_PH1_VISITS = "NUMBER OF PHASE 1 VISITS"; 
 
   if NUM_PH1_VISITS = 1 then F_1ST_PH1_VISIT = 1; 
   else F_1ST_PH1_VISIT = 0; 
   label F_1ST_PH1_VISIT = "1st PHASE 1 VISIT INDICATOR"; 
   format F_1ST_PH1_VISIT F_1ST_PH1_VISITF.; 
 
   *calculate time on phase 1 study; 
   if F_1ST_PH1_VISIT = 1 then  
      do; 
         DOE_1ST_PH1_VISIT = DOE; 
         retain DOE_1ST_PH1_VISIT; 
      end; 
   if F_PH1_VISIT = 0 then DOE_1ST_PH1_VISIT = .; *make missing for all non-
phase 1 visits; 
   if (F_PH1 = 1 and F_PH1_VISIT = 0) then PH1_YRS = 0; 
   else if F_PH1 = 1 then PH1_YRS = yrdif(DOE_1ST_PH1_VISIT, DOE, 'ACT/ACT'); 
   else PH1_YRS = 0; 
   label DOE_1ST_PH1_VISIT = "SAS DATE VALUE FOR 1ST PH1 VISIT"; 
   label PH1_YRS = "NUMBER OF YEARS ON PHASE 1 STUDY"; 
   format PH1_YRS 5.2; *5 spaces for number in all: 2 decimal places, 1 for 
decimal, which leaves 2 places left of decimal; 
 
  *calculate time that phase 1 patients spent on natural history study; 
   if F_PH1 = 1  then NH_YRS = ASTDY_YRS - PH1_YRS; 
   else NH_YRS = ASTDY_YRS; 
   label NH_YRS = "NUMBER OF YEARS IN NH STUDY"; 
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   format NH_YRS 5.2; *5 spaces for number in all: 2 decimal places, 1 for 
decimal, which leaves 2 places left of decimal; 
   
 
  if (F_PH1 = 1 and F_PH1_VISIT = 1) then ASTDY_YRS = PH1_YRS; 
  else if (F_PH1 = 1 and F_PH1_VISIT = 0) then ASTDY_YRS = 0; 
  else if F_PH1 = 0 then ASTDY_YRS = NH_YRS; 
 
   if (F_PH1_VISIT = 0 and F_PH1 = 1) then delete; *delete non-phase 1 
records for phase 1 patients;   
   if (F_PH1 = 0 and F_RIGHT_AGE = 0) then delete; *delete records for NH 
patients who aren't aged 6-26 at baseline; 
  *drop PH1_YRS NH_YRS; 
run; 
 
/*data TEST; 
   set SPEECH_NH_PH1_POST2013; 
   keep SUBJID_NPC F_PH1 ASTDY_YRS F_PH1_VISIT PH1_YRS NH_YRS; 
run;*/ 
 
*keep all natural history patients aged 6-26 years at baseline with multiple 
visits; 
data SPEECH_FINAL_NH; 
   set SPEECH_NH_PH1_POST2013  end=EOF; 
   by SUBJID_NPC; 
   if (COHORT ge 1 and COHORT le 4) then delete; 
run; 
 
 
*keep all phase 1 study patients with multiple visits; 
data SPEECH_FINAL_PH1; 
   set SPEECH_NH_PH1_POST2013  end=EOF; 
   by SUBJID_NPC; 
   if (COHORT ge 1 and COHORT le 4); 
run; 
 
/*proc freq data = SPEECH_FINAL_PH1; table AGE_NEW; run;*/ 
 
*SCI spaghetti plot macro; 
 
 
*ods path show; 
 
/*proc means data = SPEECH_FINAL_PH1; 
   var ASTDY_YRS; 
run;*/ 
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/*proc means data = SPEECH_FINAL_NH; 
   var ASTDY_YRS; 
run;*/ 
    
 
 
/*options nomgen nosymbolgen; 
ods path show; 
ods path work.sciplot(read);*/ 
 
*PH1 PLOTS; 
ods rtf file = "&PROGFOLD\figures\&PROGNAME\PH1\OUTCOME_VARS.rtf" style = 
sciplot; 
%MAKE_PLOT_PH1(DIETARY_RESTRICTION, %str(DIETARY RESTRICTION), %str(mean 
DIETARY RESTRICTION total (max = 6))); 
%MAKE_PLOT_PH1(DIMINISHED_LIP_STRENGTH, %str(DIMINISHED LIP STRENGTH), 
%str(mean DIMINISHED LIP STRENGTH total (max = 8))); 
%MAKE_PLOT_PH1(DIMINISHED_TONGUE_STRENGTH, %str(DIMINISHED TONGUE STRENGTH), 
%str(mean DIMINISHED TONGUE STRENGTH total (max = 8))); 
%MAKE_PLOT_PH1(DYSARTHRIA, %str(DYSARTHRIA), %str(mean DYSARTHRIA total (max 
= 8))); 
%MAKE_PLOT_PH1(LIQUID, %str(LIQUID), %str(mean LIQUIDtotal (max = 8))); 
%MAKE_PLOT_PH1(PENETRATION_ASP_CORRECTED, %str(PENETRATION_ASP_CORRECTED), 
%str(mean PENETRATION_ASP_CORRECTED total (max = 10))); 
%MAKE_PLOT_PH1(SOLID_FOOD, %str(SOLID FOOD), %str(mean SOLID FOOD total (max 
= 8))); 
%MAKE_PLOT_PH1(SPEECH, %str(SPEECH), %str(mean SPEECH total (max = 4))); 
%MAKE_PLOT_PH1(SWALLOWING_OUTCOME, %str(SWALLOWING_OUTCOME), %str(mean 
SWALLOWING_OUTCOME total (max = 14))); 
ods rtf close; 
 
 
 
%readonly(FIGURES); 
 
proc freq data = SPEECH_FINAL_NH; 
   table DIETARY_RESTRICTION; 
run; 
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III. F_spaghetti_MB_NH.sas 
proc format; 
   value F_PH1F  
      0 = "NATURAL HISTORY PATIENT" 
      1 = "PHASE 1 PATIENT"; 
   value F_RIGHT_AGEF 
      0 = "NOT BETWEEN 6 AND 26 YEARS OLD" 
      1 = "BETWEEN 6 AND 26 YEARS OLD"; 
   value F_PH1_VISITF 
      0 = "NATURAL HISTORY VISIT" 
      1 = "PHASE 1 VISIT"; 
   value F_1ST_PH1_VISITF 
      0 = "NOT 1ST PHASE 1 VISIT" 
      1 = "1ST PHASE 1 VISIT"; 
run; 
 
data SPEECH_FINAL; 
   set ANALYSIS.SPEECH_FINAL; 
   by SUBJID_NPC; 
   DIMINISHED_TONGUE_STRENGTH = DIMINISHED_TONGUE_STENGTH; 
   drop DIMINISHED_TONGUE_STENGTH; 
   label DIMINISHED_TONGUE_STRENGTH = "DIMINISHED TONGUE STRENGTH"; 
   if (first.SUBJID_NPC and last.SUBJID_NPC) then delete; 
   if (ASTDY_YRS = . and first.SUBJID_NPC and ASTDY = 0) then ASTDY_YRS = 0; 
   if (COHORT ge 1 and COHORT le 4) then F_PH1 = 1; 
   else F_PH1 = 0; 
   label F_PH1 = "INDICATOR FOR PHASE 1 STUDY"; 
   format F_PH1 F_PH1F.; 
 
   label F_RIGHT_AGE  = "flag for being between 6 and 26 years old"; 
   format F_RIGHT_AGE F_RIGHT_AGEF.; 
   if (first.SUBJID_NPC and AGE_NEW ge 6 and AGE_NEW le 26) then  
      do; 
         F_RIGHT_AGE = 1; 
         retain F_RIGHT_AGE; 
      end; 
    else if (first.SUBJID_NPC and (AGE_NEW lt 6 or AGE_NEW gt 26)) then  
      do; 
         F_RIGHT_AGE = 0; 
         retain F_RIGHT_AGE; 
      end; 
run; 
 
data SPEECH_NH_PH1_POST2013; *doesn't include natural history records for 
phase 1 patients; 
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  set SPEECH_FINAL; 
  by SUBJID_NPC; 
  informat DOE mmddyy10.; *get SAS date value for visit dates; 
  BASE_SAS_DATE_VALUE = mdy(1,1,2013); *get SAS date value for Jan 1, 2013; 
 
  *create indicator for phase 1 visit; 
   if(F_PH1 = 1 and yrdif(BASE_SAS_DATE_VALUE, DOE, 'ACT/ACT') > 0) then 
F_PH1_VISIT = 1; 
   else F_PH1_VISIT = 0; 
   label F_PH1_VISIT = "PHASE 1 VISIT INDICATOR"; 
   format F_PH1_VISIT F_PH1_VISITF.; 
 
   *determine first phase 1 visit; 
   if F_PH1_VISIT = 0 then NUM_PH1_VISITS = 0; 
   else NUM_PH1_VISITS = NUM_PH1_VISITS + 1; 
   retain NUM_PH1_VISITS; 
   label NUM_PH1_VISITS = "NUMBER OF PHASE 1 VISITS"; 
 
   if NUM_PH1_VISITS = 1 then F_1ST_PH1_VISIT = 1; 
   else F_1ST_PH1_VISIT = 0; 
   label F_1ST_PH1_VISIT = "1st PHASE 1 VISIT INDICATOR"; 
   format F_1ST_PH1_VISIT F_1ST_PH1_VISITF.; 
 
   *calculate time on phase 1 study; 
   if F_1ST_PH1_VISIT = 1 then  
      do; 
         DOE_1ST_PH1_VISIT = DOE; 
         retain DOE_1ST_PH1_VISIT; 
      end; 
   if F_PH1_VISIT = 0 then DOE_1ST_PH1_VISIT = .; *make missing for all non-
phase 1 visits; 
   if (F_PH1 = 1 and F_PH1_VISIT = 0) then PH1_YRS = 0; 
   else if F_PH1 = 1 then PH1_YRS = yrdif(DOE_1ST_PH1_VISIT, DOE, 'ACT/ACT'); 
   else PH1_YRS = 0; 
   label DOE_1ST_PH1_VISIT = "SAS DATE VALUE FOR 1ST PH1 VISIT"; 
   label PH1_YRS = "NUMBER OF YEARS ON PHASE 1 STUDY"; 
   format PH1_YRS 5.2; *5 spaces for number in all: 2 decimal places, 1 for 
decimal, which leaves 2 places left of decimal; 
 
  *calculate time that phase 1 patients spent on natural history study; 
   if F_PH1 = 1  then NH_YRS = ASTDY_YRS - PH1_YRS; 
   else NH_YRS = ASTDY_YRS; 
   label NH_YRS = "NUMBER OF YEARS IN NH STUDY"; 
   format NH_YRS 5.2; *5 spaces for number in all: 2 decimal places, 1 for 
decimal, which leaves 2 places left of decimal; 
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  if (F_PH1 = 1 and F_PH1_VISIT = 1) then ASTDY_YRS = PH1_YRS; 
  else if (F_PH1 = 1 and F_PH1_VISIT = 0) then ASTDY_YRS = 0; 
  else if F_PH1 = 0 then ASTDY_YRS = NH_YRS; 
 
   if (F_PH1_VISIT = 0 and F_PH1 = 1) then delete; *delete non-phase 1 
records for phase 1 patients;   
   if (F_PH1 = 0 and F_RIGHT_AGE = 0) then delete; *delete records for NH 
patients who aren't aged 6-26 at baseline; 
  *drop PH1_YRS NH_YRS; 
run; 
 
/*data TEST; 
   set SPEECH_NH_PH1_POST2013; 
   keep SUBJID_NPC F_PH1 ASTDY_YRS F_PH1_VISIT PH1_YRS NH_YRS; 
run;*/ 
 
*keep all natural history patients aged 6-26 years at baseline with multiple 
visits; 
data SPEECH_FINAL_NH; 
   set SPEECH_NH_PH1_POST2013  end=EOF; 
   by SUBJID_NPC; 
   if (COHORT ge 1 and COHORT le 4) then delete; 
run; 
 
 
*keep all phase 1 study patients with multiple visits; 
data SPEECH_FINAL_PH1; 
   set SPEECH_NH_PH1_POST2013  end=EOF; 
   by SUBJID_NPC; 
   if (COHORT ge 1 and COHORT le 4); 
run; 
 
/*proc freq data = SPEECH_FINAL_PH1; table AGE_NEW; run;*/ 
*SCI spaghetti plot macro; 
ods rtf file = "&PROGFOLD\figures\&PROGNAME\NH\DIETARY_RESTRICTION.rtf" style 
= sciplot; 
title 'Natural History Patients'; 
%MAKE_PLOT_NH(DIETARY_RESTRICTION, %str(DIETARY RESTRICTION), %str(mean 
PENETRATION_ASP_CORRECTED total (max = 10))); 
ods rtf close; 
 
ods rtf file = "&PROGFOLD\figures\&PROGNAME\NH\DIMINISHED_LIP_STRENGTH.rtf" 
style = sciplot; 
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title 'Natural History Patients'; 
%MAKE_PLOT_NH(DIMINISHED_LIP_STRENGTH, %str(LIP STRENGTH), %str(mean 
DIMINISHED LIP STRENGTH total (max = 10))); 
ods rtf close; 
 
ods rtf file = 
"&PROGFOLD\figures\&PROGNAME\NH\DIMINISHED_TONGUE_STRENGTH.rtf" style = 
sciplot; 
title 'Natural History Patients'; 
%MAKE_PLOT_NH(DIMINISHED_TONGUE_STRENGTH, %str(TONGUE STRENGTH), %str(mean 
DIMINISHED TONGUE STRENGTH total (max = 10))); 
ods rtf close; 
 
ods rtf file = "&PROGFOLD\figures\&PROGNAME\NH\DYSARTHRIA.rtf" style = 
sciplot; 
title 'Natural History Patients'; 
%MAKE_PLOT_NH(DYSARTHRIA, %str(DYSARTHRIA), %str(mean DYSARTHRIA total (max = 
10))); 
ods rtf close; 
 
ods rtf file = "&PROGFOLD\figures\&PROGNAME\NH\LIQUID.rtf" style = sciplot; 
title 'Natural History Patients'; 
%MAKE_PLOT_NH(LIQUID, %str(LIQUID), %str(mean LIQUID total (max = 10))); 
ods rtf close; 
 
ods rtf file = "&PROGFOLD\figures\&PROGNAME\NH\PENETRATION_ASP_CORRECTED.rtf" 
style = sciplot; 
title 'Natural History Patients'; 
%MAKE_PLOT_NH(PENETRATION_ASP_CORRECTED, %str(PENETRATION ASP), %str(mean 
PENETRATION_ASP_CORRECTED total (max = 10))); 
ods rtf close; 
 
ods rtf file = "&PROGFOLD\figures\&PROGNAME\NH\SOLID_FOOD.rtf" style = 
sciplot; 
title 'Natural History Patients'; 
%MAKE_PLOT_NH(SOLID_FOOD, %str(SOLID FOOD), %str(mean SOLID FOOD total (max = 
10))); 
ods rtf close; 
 
ods rtf file = "&PROGFOLD\figures\&PROGNAME\NH\SPEECH.rtf" style = sciplot; 
title 'Natural History Patients'; 
%MAKE_PLOT_NH(SPEECH, %str(SPEECH), %str(mean SPEECH total (max = 10))); 
ods rtf close; 
 
ods rtf file = "&PROGFOLD\figures\&PROGNAME\NH\SWALLOWING_OUTCOME.rtf" style 
= sciplot; 
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title 'Natural History Patients'; 
%MAKE_PLOT_NH(SWALLOWING_OUTCOME, %str(SWALLOWING OUTCOME), %str(SWALLOWING 
OUTCOME total (max = 10))); 
ods rtf close; 
%readonly(FIGURES); 
IV. Mixed_Models.sas 
* Definition of program-specific macros; 
*macro for mixed models; 
%macro MIXED (OUTCOME = , DATA = ); 
 
ods rtf file = "E:\Proj\Cydan\Programs\MB programs\OUT\MIXED 
MODELS\&OUTCOME..rtf"; 
ods exclude ModelInfo ClassLevels Dimensions NObs IterHistory CovParms; 
ods output SOLUTION_F = solutionF(keep = EFFECT ESTIMATE PROBT); 
*TIME-ONLY MODEL; 
title "&OUTCOME"; 
title2 "TIME ONLY"; 
proc mixed data=&DATA method=reml covtest asycov asycorr ic; 
   class SUBJID_NPC; 
   id SUBJID_NPC; 
   model &OUTCOME =ASTDY_YRS/solution cl influence residual; 
   random INTERCEPT /patient=SUBJID_NPC type=un gcorr; 
run; 
 
data SOLUTION_F; 
   set SOLUTION_F; 
   format ESTIMATE 5.3 
          PROBT    5.3; 
run; 
 
 
 
/**PHASE 1 INDICATOR-ONLY MODEL; 
title2 "PHASE 1 INDICATOR ONLY"; 
proc mixed data=&DATA method=reml covtest asycov asycorr ic; 
   class SUBJID_NPC; 
   id SUBJID_NPC; 
   model &OUTCOME =F_PH1 /solution cl influence residual; 
   random INTERCEPT /patient=SUBJID_NPC type=un gcorr; 
run;*/ 
 
*BOTH MAIN EFFECTS MODEL; 
title2 "BOTH MAIN EFFECTS"; 
proc mixed data=&DATA method=reml covtest asycov asycorr ic; 
   class SUBJID_NPC; 
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   id SUBJID_NPC; 
   model &OUTCOME =F_PH1 ASTDY_YRS /solution cl influence residual; 
   random INTERCEPT /patient=SUBJID_NPC type=un gcorr; 
run; 
 
*BOTH MAIN EFFECTS AND INTERACTION MODEL; 
title2 "BOTH MAIN EFFECTS AND INTERACTION"; 
proc mixed data=&DATA method=reml covtest asycov asycorr ic; 
   class SUBJID_NPC; 
   id SUBJID_NPC; 
   model &OUTCOME =F_PH1 ASTDY_YRS F_PH1 * ASTDY_YRS/solution cl influence 
residual; 
   random INTERCEPT /patient=SUBJID_NPC type=un gcorr; 
   estimate "natural history" INTERCEPT 0 ASTDY_YRS 1 F_PH1 0 F_PH1 * 
ASTDY_YRS 0/cl; 
   estimate "phase 1" INTERCEPT 0 ASTDY_YRS 1 F_PH1 0 F_PH1 * ASTDY_YRS 1/cl; 
run; 
ods rtf close; 
%mend MIXED; 
 
 
*======================================= MAIN PROGRAM 
=========================================>; 
proc format; 
   value F_PH1F  
      0 = 'NOT IN PHASE 1 STUDY' 
      1 = 'IN PHASE 1 STUDY'; 
   value F_RIGHT_AGEF 
      0 = "NOT BETWEEN 6 AND 26 YEARS OLD" 
      1 = "BETWEEN 6 AND 26 YEARS OLD"; 
   value F_PH1_VISITF 
      0 = "NATURAL HISTORY VISIT" 
      1 = "PHASE 1 VISIT"; 
   value F_1ST_PH1_VISITF 
      0 = "NOT 1ST PHASE 1 VISIT" 
      1 = "1ST PHASE 1 VISIT"; 
run; 
 
 
* Data steps; 
data SPEECH_FINAL; 
   set ANALYSIS.SPEECH_FINAL (rename=(DIMINISHED_TONGUE_STENGTH = 
DIMINISHED_TONGUE_STRENGTH)); 
   label DIMINISHED_TONGUE_STRENGTH = "DIMINISHED TONGUE STRENGTH"; 
run; 
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*we want all phase 1 patients with multiple visits and NH patients aged 6-26 
at baseline with multiple visits; 
data SPEECH_FINAL_SUBSET; 
   set SPEECH_FINAL; 
   by SUBJID_NPC; 
   if (first.SUBJID_NPC and last.SUBJID_NPC) then delete; 
   if(first.SUBJID_NPC and ASTDY = 0) then ASTDY_YRS = 0; 
   if (COHORT ge 1 and COHORT le 4) then F_PH1 = 1; 
   else F_PH1=0; 
   format F_PH1 F_PH1F.; 
   if F_PH1 = 0 then  
      if (first.SUBJID_NPC and AGE_NEW ge 6 and AGE_NEW le 26) then /*if NH 
patient is in desired age range at baseline*/ 
      do; 
         F_RIGHT_AGE = 1; 
         retain F_RIGHT_AGE; 
      end; 
    else if (first.SUBJID_NPC and (AGE_NEW lt 6 or AGE_NEW gt 26)) then  
      do; 
         F_RIGHT_AGE = 0; 
         retain F_RIGHT_AGE; 
      end; 
   if (F_PH1 = 0 and F_RIGHT_AGE = 0) then delete; *get rid of NH patients 
that aren't between 6 and 26 years old at baseline; 
   label F_RIGHT_AGE  = "flag for being between 6 and 26 years old"; 
   format F_RIGHT_AGE F_RIGHT_AGEF.; 
 
run; 
 
*need to get rid of time spent on natural history study for phase 1 patients; 
data SPEECH_NH_PH1_POST2013; *doesn't include natural history records for 
phase 1 patients; 
  set SPEECH_FINAL_SUBSET; 
  by SUBJID_NPC; 
  informat DOE mmddyy10.; *get SAS date value for visit dates; 
  BASE_SAS_DATE_VALUE = mdy(1,1,2013); *get SAS date value for Jan 1, 2013; 
 
  *create indicator for phase 1 visit; 
   if(F_PH1 = 1 and yrdif(BASE_SAS_DATE_VALUE, DOE, 'ACT/ACT') > 0) then 
F_PH1_VISIT = 1; 
   else F_PH1_VISIT = 0; 
   label F_PH1_VISIT = "PHASE 1 VISIT INDICATOR"; 
   format F_PH1_VISIT F_PH1_VISITF.; 
 
   *determine first phase 1 visit; 
   if F_PH1_VISIT = 0 then NUM_PH1_VISITS = 0; 
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   else NUM_PH1_VISITS = NUM_PH1_VISITS + 1; 
   retain NUM_PH1_VISITS; 
   label NUM_PH1_VISITS = "NUMBER OF PHASE 1 VISITS"; 
 
   if NUM_PH1_VISITS = 1 then F_1ST_PH1_VISIT = 1; 
   else F_1ST_PH1_VISIT = 0; 
   label F_1ST_PH1_VISIT = "1st PHASE 1 VISIT INDICATOR"; 
   format F_1ST_PH1_VISIT F_1ST_PH1_VISITF.; 
 
   *calculate time on phase 1 study; 
   if F_1ST_PH1_VISIT = 1 then  
      do; 
         DOE_1ST_PH1_VISIT = DOE; 
         retain DOE_1ST_PH1_VISIT; 
      end; 
   if F_PH1_VISIT = 0 then DOE_1ST_PH1_VISIT = .; *make missing for all non-
phase 1 visits; 
   if (F_PH1 = 1 and F_PH1_VISIT = 0) then PH1_YRS = 0; 
   else if F_PH1 = 1 then PH1_YRS = yrdif(DOE_1ST_PH1_VISIT, DOE, 'ACT/ACT'); 
   else PH1_YRS = 0; 
   label DOE_1ST_PH1_VISIT = "SAS DATE VALUE FOR 1ST PH1 VISIT"; 
   label PH1_YRS = "NUMBER OF YEARS ON PHASE 1 STUDY"; 
   format PH1_YRS 5.2; *5 spaces for number in all: 2 decimal places, 1 for 
decimal, which leaves 2 places left of decimal; 
 
  *calculate time that phase 1 patients spent on natural history study; 
   if F_PH1 = 1  then NH_YRS = ASTDY_YRS - PH1_YRS; 
   else NH_YRS = ASTDY_YRS; 
   label NH_YRS = "NUMBER OF YEARS IN NH STUDY"; 
   format NH_YRS 5.2; *5 spaces for number in all: 2 decimal places, 1 for 
decimal, which leaves 2 places left of decimal; 
   
 
  if (F_PH1 = 1 and F_PH1_VISIT = 1) then ASTDY_YRS = PH1_YRS; 
  else if (F_PH1 = 1 and F_PH1_VISIT = 0) then ASTDY_YRS = 0; 
  else if F_PH1 = 0 then ASTDY_YRS = NH_YRS; 
 
   if (F_PH1_VISIT = 0 and F_PH1 = 1) then delete; *delete non-phase 1 
records for phase 1 patients;   
  *drop PH1_YRS NH_YRS; 
run; 
 
data TEST; 
   set SPEECH_NH_PH1_POST2013; 
   keep SUBJID_NPC F_PH1 ASTDY_YRS F_PH1_VISIT PH1_YRS NH_YRS; 
run; 
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* Proc code; 
*run mixed models macro for each outcome of interest; 
%MIXED(OUTCOME = DIETARY_RESTRICTION, DATA = SPEECH_NH_PH1_POST2013); 
%MIXED(OUTCOME = DIMINISHED_LIP_STRENGTH, DATA = SPEECH_NH_PH1_POST2013); 
%MIXED(OUTCOME = DIMINISHED_TONGUE_STRENGTH, DATA = SPEECH_NH_PH1_POST2013); 
%MIXED(OUTCOME = DYSARTHRIA, DATA = SPEECH_NH_PH1_POST2013); 
%MIXED(OUTCOME = LIQUID, DATA = SPEECH_NH_PH1_POST2013); 
%MIXED(OUTCOME = PENETRATION_ASP_CORRECTED, DATA = SPEECH_NH_PH1_POST2013); 
%MIXED(OUTCOME = SOLID_FOOD, DATA = SPEECH_NH_PH1_POST2013); 
%MIXED(OUTCOME = SPEECH, DATA = SPEECH_NH_PH1_POST2013); 
%MIXED(OUTCOME = SWALLOWING_OUTCOME, DATA = SPEECH_NH_PH1_POST2013); 
 
 
 
 
 
 
*******************************************END OF MIXED MODELS FOR 
SPEECH_FINAL 
DATASET**********************************************************************
*********; 
 
 
 
 
proc sort data = ANALYSIS.SPEECH_FINAL; 
   by SUBJID_NPC ASTDY_YRS; 
run; 
 
title 'SPEECH_FINAL'; 
proc print data = ANALYSIS.SPEECH_FINAL (obs = 20); 
   by SUBJID_NPC; 
   var SUBJID_NPC SUBJID_CDA ASTDY_YRS DIETARY_RESTRICTION 
DIMINISHED_LIP_STRENGTH DIMINISHED_TONGUE_STENGTH DYSARTHRIA LIQUID 
PENETRATION_ASP_CORRECTED SOLID_FOOD SPEECH SWALLOWING_OUTCOME; 
run; 
ods rtf close; 
 
 
/*proc freq data = SPEECH_FINAL; 
   tables SUBJID_CDA*COHORT; 
run;*/ 
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/*proc freq data = SPEECH_FINAL; 
   tables F_PH1 ASTDY_YRS; 
run;*/ 
 
/* END OF PROGRAM */ 
54 
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